医学信息2019，Vol.32Issue(3)：148-150,3.DOI:10.3969/j.issn.1006-1959.2019.03.048
恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察
Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma
刘贤丰 1李子俊1
作者信息
- 1. 江西省九江市第一人民医院胸心外科,江西 九江 332000
- 折叠
摘要
Abstract
Objective To compare the clinical efficacy of recombinant human endostatin injection (Endo) combined with pemetrexed and cisplatin chemotherapy with pemetrexed plus cisplatin in the treatment of advanced lung adenocarcinoma.Methods 81 patients with advanced lung adenocarcinoma diagnosed by histopathology or cytology were randomly divided into observation group (41 cases) and control group (40 cases) . Both groups were given pemetrexed + cisplatin (PP regimen) chemotherapy, and the observation group was given en-degree treatment on this basis. The short-term clinical efficacy of the two groups was evaluated. The quality of life (KBS) score was used to evaluate the quality of life before and after treatment and the adverse reactions during the treatment. The median progression time was calculated.Results The effective rate of the observation group was 46.15％, which was higher than that of the control group 37.50％, the difference was statistically significant (P ＜0.05) .The median tumor progression time of the observation group was 8.65 months, which was higher than the control group of 5.31 months, the difference was statistically significant (P＜0.05) .There was no significant difference in the quality of life scores and adverse reactions between the two groups (P＞0.05) .Conclusion Endo combined with pemetrexed plus cisplatin in the treatment of advanced lung adenocarcinoma can improve the short-term clinical efficacy, prolong the tumor progression time, improve the quality of life, and does not increase adverse reactions, and has good clinical efficacy and safety.关键词
恩度/培美曲塞/顺铂/肺腺癌Key words
Endo/Pemetrexed/Cisplatin/Lung adenocarcinoma分类
医药卫生引用本文复制引用
刘贤丰,李子俊..恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察[J].医学信息,2019,32(3):148-150,3.
